{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-24-055288","form_type":"8-K/A","ticker":"ABVC","cik":"0001173313","company_name":"ABVC BIOPHARMA, INC.","filed_at":"2024-06-24T23:59:59+00:00","discovered_at":"2026-05-14T18:03:17.529339+00:00","generated_at":"2026-06-01T02:23:49.358261+00:00","sec_items":["1.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"confidence":"high","headline":"ABVC BioPharm amends ophthalmology license deal to allow incremental milestone payments","bullets":["ABVC and BIOFIRST amended licensing agreement with ForSeeCon Eye Corp (FEYE) covering ophthalmology pipeline including Vitargus.","Second milestone payment of $3.5M can now be paid incrementally (e.g., $100k) at any time, rather than a single lump sum.","Amendment dated June 18, 2024; all other terms of the original March 25, 2024, license remain unchanged."],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-24-055288","json":"https://secwatch.observer/filing/0001213900-24-055288.json","markdown":"https://secwatch.observer/filing/0001213900-24-055288.md","text":"https://secwatch.observer/filing/0001213900-24-055288.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1173313/000121390024055288/0001213900-24-055288-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1173313/000121390024055288/ea0208383-8ka1_abvcbio.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-01T02:23:49.358261+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}